"The Evaluation of Stimulant Withdrawal"

• Status: Withdrawn
• Trial end date: 2011-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Aaron J. Janowsky
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Methamphetamine

Criteria

Inclusion Criteria:

• Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center

• Must meet the clinical definition for methamphetamine dependence

• Self-reported methamphetamine use within 10 days of entering the study

• Must be able to understand and sign the consent form

Exclusion Criteria:

• Dependent on any other drug except nicotine, caffeine, marijuana and alcohol

• Pregnant or nursing mothers

• Psychosis

• Dementia

• Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)

• History of withdrawal seizures or delirium tremors

• Use of MAO inhibitors within the last two weeks

• Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal